# Efficacy and Safety of LC-Z300-01 in Chinese With Type 2 Diabetes

> **NCT06847178** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Diabetes
- Type 2 Diabetes

## Interventions

- **DIETARY_SUPPLEMENT:** Placebo twice daily in blinding
- **DRUG:** Low-dose LC-Z300-01 twice daily in blinding
- **DRUG:** High-dose LC-Z300-01 twice daily in blinding
- **DRUG:** High-dose LCZ300-1 twice daily in open-label

## Key facts

- **NCT ID:** NCT06847178
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-11-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06847178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06847178, "Efficacy and Safety of LC-Z300-01 in Chinese With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06847178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*